Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Relay Therapeutics Inc
RLAY
Healthcare
Biotechnology
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The...
Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Ka), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:RLAY)
New Post
View:
Posts & Comments
Threaded Posts
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 09, 2024 10:15am
Relay Therapeutics Announces Positive Interim Data for RLY-2
NEWS: $RLAY Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival9.2-month median PFS in heavily pre-treated patients with PI3K
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 02, 2024 5:00pm
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Hea
Breaking News: $RLAY Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a
...more
Access North American AND Australian listed and Pre-IPO opportunities – here!
posted Dec 27, 2024 9:00am by
Stockhouse Publishing Ltd.
-
|
For the first time on Stockhouse, Canadian investors can access ASX-listed opportunities through our partnership with HotCopper in Australia, opening doors to high-potential investments at the click of a button. Learn more here… ...read more
(4)
•••
Gamaliel
X
View Profile
View Bullboard History
Post by
Gamaliel
on Aug 09, 2021 11:49am
To the Moon!
https://discord.gg/P4fHqHzkcN
(4)
•••
Gamaliel
X
View Profile
View Bullboard History
Post by
Gamaliel
on Aug 09, 2021 11:47am
To the Moon!!!
https://discord.gg/P4fHqHzkcN
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight
A potential breakthrough in spinal cord and optic nerve injury treatment